Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 177-186

  O'Reilly, S ^a   Fleming, G F ^a   Barker, S D ^a   Walczak, J R ^a   Bookman, M A ^a   McGuire III, W P ^a   Schilder, R J ^a   Alvarez, R D ^a   Armstrong, D K ^a   Horowitz, I R ^a   Ozols, R F ^a   Rowinsky, E K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; NEUTROPENIA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031014626     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.177     Document Type: Article

References (44)

1. Rowinsky EK, Donehower RC: Drug therapy: Paclitaxel (Taxol). N Engl J Med 332:1004-1114, 1995
2. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
3. Thigpen T, Blessing J, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecological Oncology Group study. J Clin Oncol 12:1748-1753, 1994
4. Einzig AI, Wiernik P, Sasloff J, et al: Phase II study and long-term follow up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992
5. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
6. Kohn EC, Sarosy G, Bicher A, et al: Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18-24, 1994
7. Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Treatment Referral Center 9103. J Clin Oncol 11:2405-2410, 1993
8. Rowinsky EK, Gilbert M, McGuire WP et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
9. Bookman MA, McGuire WP, Kilpatrick D, et al: Phase-1 Gynecologic Oncology Group (GOG) study of paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:271, 1995 (abstr)
10. Arbuck SG, Canetta R, Onetto N, et al: Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Ontol 20:31-39, 1993 (suppl 3)
11. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
12. Potmesil MP: Camptothecins: From bench research to hospital wards. Cancer Res 54:1431-1439, 1994
13. Chen AY, Liu LF: DNA topoisomerases: Essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 34:191-218, 1994
14. Froelich-Ammon SJ, Osheroff N: Topoisomerase poisons: Harnessing the dark side of enzyme mechanism. J Biol Chem 270:21429-21432, 1995
15. Ryan AJ, Squires S, Strutt HL, Johnson RT: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 19:3295-3300, 1991
16. Pommier Y, Leteurtre F, Fesen MR, et al: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12:530-542, 1994
17. Rowinsky E, Grochow L, Hendricks C, et al: Phase I and pharmacologic study of topotecan (SK&F 104864): A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
18. Kamajarian HM, Beran M, Ellis A, et al: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed leukemia. Blood 81:1146-1151, 1993
19. Rowinsky EK, Adjei A, Donehower RC, et al: A phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-2203, 1994
20. Schiller JH, Kim K, Johnson D: Phase II study of topotecan in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 13:330, 1994 (abstr)
21. Ardizzoni A, Hansen H, Dombernowsky P, et al: Phase II study of topotecan in pretreated small cell lung cancer (sclc). Proc Am Soc Clin Oncol 13:336, 1994 (abstr)
22. Robert F, Wheeler RH, Molthrop DC, et al: Phase II study of topotecan in advanced head and neck cancer: Identification of an active new agent. Proc Am Soc Clin Oncol 13:281, 1994 (abstr)
23. Eisenhauer EA, Wainman G, Boos G, et al: Phase II trials of topotecan in patients with malignant glioma and soft tissue sarcoma. Proc Am Soc Clin Oncol 13:175, 1994 (abstr)
24. Noda K, Sasaki H, Yamamoto T, et al: Phase II trial of topotecan for cervical cancer of the uterus. Proc Am Soc Clin Oncol 15:280, 1996 (abstr)
25. Kudelka A, Tresukosol D, Edwards C, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
26. Armstrong D, Rowinsky E, Donehower RC, et al: Phase II study of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:275, 1995 (abstr)
27. Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol (in press)
28. Gordon A, Bookman M, Malstrom H, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 15:282, 1996 (abstr)
29. Carmichael J, Gordon A, Malfetano J, et al: Topotecan, a new active drug, versus paclitaxel in advanced ovarian carcinoma: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 15:283, 1996 (abstr)
30. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
31. Markman M, Hoskins W: Response to salvage chemotherapy in ovarian cancer. A critical need for precise definitions of the treated population. J Clin Oncol 10:513-514, 1992
32. Longnecker SM, Donehower RC, Cates AE, et al: High performance liquid chromatographic assay for Taxol (NSC 125973) in human plasma and urine pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1986
33. Weiss M: Model-independent assessment of accumulation kinetics based on moments of drug disposition curves. Eur J Clin Pharmacol 27:355-358, 1984
34. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of topotecan. Drug Metab Dispos 20:706-712, 1992
35. Chiou WL: Critical examination of the potential error in pharmacokinetic studies using linear trapezoidal rule method for the calculation of area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546, 1978
36. Peerboom D, Donehower RC, Eisenhauer EA, et al: Successful retreatment with Taxol after major hypersensitivity reactions. J Clin Oncol 11:885-890, 1993
37. Lilenbaum RC, Ratain MJ, Miller AA, et al: Phase I study of paclitaxel and topotecan in patients with advanced tumors: A Cancer and Leukemia Group B study. J Clin Oncol 13:2230-2237, 1995
38. Eisenhauer, E., ten Bokkel Huinink W, Swenerton KD, et al: European-Canadian randomized trial of Taxol in relapsed ovarian cancer: High versus low dose and long versus short infusion. J Clin Oncol 12:2654-66, 1994
39. Miller AA, Lillenbaum RC, Lynch TJ, et al: Treatment related fatal sepsis from topotecan/ cisplatin and topotecan/paclitaxel. J Clin Oncol 14:1964-1965, 1996
40. Rowinsky E, Grochow L, Kaufmann S, et al: Sequence-dependent effects of topotecan and cisplatin in a phase I and pharmacokinetic study. Proc Am Soc Clin Oncol 13:142, 1994 (abstr)
41. Chou TC, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of Taxol, topotecan and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524, 1994
42. Rowinsky EK, Citardi M, Noe DA, et al: Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 119:737-743, 1993
43. Kennedy MJ, Zahurak ML, Donehower RC. et al: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously-treated metastatic breast cancer. J Clin Oncol 14:783-791, 1996
44. Holmes FA: Combination chemotherapy with Taxol in metastatic breast cancer. Ann Oncol 5:17-22, 1994 (suppl 6)